- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Tengion Inc (TNGN)
| Open: | 0.3000 | Day's Range: | 0.2500 - 0.3300 | Volume: | 68,870 | Bid: | 0.2800 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 0.2950 | 52wk Range: | 0.2500 - 1.6000 | 1-Yr Rtn: | -78.52% | Ask: | 0.3200 |
Key Statistics for TNGN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -0.3800 |
| Est. EPS (USD) (12/2012) | -0.7800 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 7.89 |
| Shares Outstanding (M) | 24.67 |
| Enterprise Value (M USD) (ttm) | 5.10 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 38.2361 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/09/2012 |
More TNGN Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for TNGN
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for TNGN
Tengion Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues. The Company currently creates functional neo-organs and neo-tissues using a patient's own cells, or autologous cells, in conjunction with its Organ Regeneration Platform.
| David I ScheerChairman/Co-Founder | John L MiclotPresident/CEO |
| A Brian DavisVP:Finance/CFO | Sunita B ShethVP/Chief Medical Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page